DSS damages the intestinal epithelial barrier, which normally separates intestinal contents from underlying tissue. This injury increases exposure of immune cells and mucosal tissues to substances within the intestinal lumen. The resulting loss of barrier integrity connects epithelial damage with immune activation and inflammatory signaling, making barrier injury a central feature for studying colitis-related disease mechanisms.
Once the epithelial barrier is compromised, luminal substances can reach tissues that are normally more protected. Their exposure stimulates immune activation and inflammatory signaling within the intestinal mucosa. This sequence allows researchers to examine how an initial structural injury progresses into measurable intestinal inflammation, rather than assessing inflammatory activity independently from epithelial damage.
Disease severity can be evaluated through several complementary findings, including weight loss, diarrhea, and rectal bleeding. Researchers can also examine colon length, tissue pathology, and inflammatory markers. Combining clinical, anatomical, microscopic, and molecular measurements provides a broader assessment than relying on one symptom and supports comparisons among experimental groups.
Therapeutic effects are assessed by comparing disease-related outcomes between experimental groups. Improvements in clinical signs, colon length, tissue pathology, or inflammatory markers can indicate reduced intestinal injury or inflammation. Using multiple endpoints helps determine whether an intervention changes the overall disease phenotype rather than producing an apparent benefit in only one measured feature.
A typical study administers DSS in drinking water to laboratory animals, then monitors the resulting disease-related changes. Researchers record clinical signs such as weight loss, diarrhea, and rectal bleeding, followed by evaluation of colon length, tissue pathology, and inflammatory markers. These measurements create a structured basis for analyzing mucosal injury and treatment response.
This experimental approach is useful when investigators need to study intestinal mucosal injury, inflammatory mechanisms, or the potential efficacy of treatments for inflammatory bowel disease. Because it produces observable clinical, anatomical, pathological, and inflammatory outcomes, the model supports comparative testing of interventions and examination of how candidate therapies affect intestinal disease features.